Patents Assigned to Zealand Pharma A/S
-
Publication number: 20110312878Abstract: The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage comprising a pharmacologically active peptide sequence (X) and a stabilising peptide sequence (Z) of 4-20 amino acid residues covalently bound to X.Type: ApplicationFiled: February 15, 2011Publication date: December 22, 2011Applicant: Zealand Pharma A/SInventor: Bjarne Due Larsen
-
Publication number: 20110293587Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: December 15, 2008Publication date: December 1, 2011Applicant: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
-
Publication number: 20110293586Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: December 15, 2008Publication date: December 1, 2011Applicant: ZEALAND PHARMA A/SInventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengern Daugaard
-
Publication number: 20110286982Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: December 15, 2008Publication date: November 24, 2011Applicant: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
-
Publication number: 20110286981Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: December 15, 2008Publication date: November 24, 2011Applicant: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
-
Patent number: 8026272Abstract: Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.Type: GrantFiled: October 30, 2009Date of Patent: September 27, 2011Assignee: Zealand Pharma A/SInventors: Bjarne Due Larsen, Jørgen Søberg Petersen, Ketil Jørgen Haugan, John A. Butera, James K. Hennan, Edward H. Kerns, Evgueni Lvovich Piatnitski
-
Patent number: 7994122Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject. In particular, the invention provides novel glucagon analogue peptides effective in such methods and in the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: GrantFiled: June 16, 2008Date of Patent: August 9, 2011Assignee: Zealand Pharma A/SInventors: Ditte Riber, Eddi Meier, Trine Skovlund Ryge, Jens Rosengren Daugaard
-
Publication number: 20110152186Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues.Type: ApplicationFiled: December 21, 2009Publication date: June 23, 2011Applicant: Zealand Pharma A/SInventors: Bjarne Due LARSEN, Yvette Miata Petersen
-
Patent number: 7935786Abstract: The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage comprising a pharmacologically active peptide sequence (X) and a stabilising peptide sequence (Z) of 4-20 amino acid residues covalently bound to X.Type: GrantFiled: May 25, 2007Date of Patent: May 3, 2011Assignee: Zealand Pharma A/SInventor: Bjarne Due Larsen
-
Publication number: 20110098222Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues.Type: ApplicationFiled: December 21, 2009Publication date: April 28, 2011Applicant: Zealand Pharma A/SInventors: Bjarne Due LARSEN, Yvette Miata Petersen
-
Publication number: 20100204105Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject. In particular, the invention provides novel glucagon analogue peptides effective in such methods and in the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: June 16, 2008Publication date: August 12, 2010Applicant: Zealand Pharma A/SInventors: Ditte Riber, Eddi Meier, Trine Skovlund Ryge, Jens Rosengren Daugaard
-
Patent number: 7749969Abstract: N- or C-terminally modified small peptides having antiarrhythmic properties are disclosed, and in particular small peptides that possess improved pharmacokinetic properties such as having a reduced tendency to inhibit the activity of isozyme 3A4 of cytochrome P 450 oxidase. The invention further relates to uses of said compounds in the preparation of a medicament, and to pharmaceutical compositions comprising said compounds.Type: GrantFiled: July 7, 2006Date of Patent: July 6, 2010Assignees: Zealand Pharma A/S, WyethInventors: Bjarne Due Larsen, Edward H. Kerns
-
Patent number: 7745403Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues.Type: GrantFiled: November 9, 2006Date of Patent: June 29, 2010Assignee: Zealand Pharma A/SInventors: Bjarne Due Larsen, Yvette Miata Petersen
-
Patent number: 7737113Abstract: Disclosed are novel peptides including antiarrhythmic peptides that have improved stability. Further disclosed are compositions that include such peptides and methods of using the compositions particularly as medicaments.Type: GrantFiled: February 4, 2004Date of Patent: June 15, 2010Assignee: Zealand Pharma A/SInventors: Bjarne Due Larsen, Jørgen Søberg Petersen, Eddi Meier, Anne Louise Kjolbye, Niklas Rye Jorgensen, Morten Schak Nielsen, James B. Martins, Niels-Henrik Holstein-Rathlou
-
Publication number: 20100048462Abstract: The present invention provides PTH peptides which are cyclised substitution analogues of the truncated PTH fragment PTH (1-17) and which preferably retain the desired or similar biological activity of human PTH (1-34).Type: ApplicationFiled: December 6, 2007Publication date: February 25, 2010Applicant: Zealand Pharma A/SInventors: Trine Skovlund Ryge, Martin Stahlhut, Carsten Boye Knudsen, Bjarne Due Larsen
-
Patent number: 7622496Abstract: Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.Type: GrantFiled: December 21, 2006Date of Patent: November 24, 2009Assignees: Zealand Pharma A/S, WyethInventors: Bjarne Due Larsen, Jørgen Søberg Petersen, Ketil Jørgen Haugan, John A. Butera, James K. Hennan, Edward H. Kerns, Evgueni L. Piatnitski
-
Patent number: 7585839Abstract: Disclosed are novel peptides including antiarrhythmic peptides that have improved stability. Further disclosed are compositions that include such peptides and methods of using the compositions particularly as medicaments.Type: GrantFiled: August 22, 2003Date of Patent: September 8, 2009Assignee: Zealand Pharma A/SInventors: Bjarne Due Larsen, Jorgen Soberg Petersen, Eddi Meier, Anne Louise Kjolbye, Niklas Rye Jorgensen, Morten Schak Neilsen, Neils-Henrik Holstein-Rathlou, James B. Martins, Peter Holme Jensen
-
Publication number: 20090208565Abstract: The present invention discloses compositions comprising a stabilized Exendin-4 (1-39) and related compounds. The invention describes stabilized Exendin-4 agonists that include at least one modified amino acid residue particularly at positions Gln13, Met14, Trp25, or Asn28 of the Exendin-4 (1-39) molecule. Disclosed are preferred modifications of deaminated, hydrolyzed, oxidized, or isomerized reaction products of the specified amino acid residues corresponding to the same positions in the Exendin-4 (1-39) molecule. The invention also relates to methods of making and using the stabilized Exendin compounds, such as for the treatment of diabetes.Type: ApplicationFiled: May 4, 2009Publication date: August 20, 2009Applicant: Zealand Pharma A/SInventors: Kirsten Ebbehoj, Trine Jepsen, Carsten Boye Knudsen, Bjarne Due Larsen, David Knott
-
Patent number: 7563770Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g. as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy.Type: GrantFiled: May 4, 2006Date of Patent: July 21, 2009Assignee: Zealand Pharma A/SInventors: Bjarne Due Larsen, Yvette Miata Petersen
-
Patent number: 7550425Abstract: Disclosed are a variety of peptide conjugates represented by the following general formula: R1-Z-X-Z?-R2 including methods of making and using such conjugates. Also provided are antibodies that specifically bind the peptide conjugates. The present invention has a wide spectrum of important applications including use in the treatment of disorders impacted by nociceptin and related opioid-like peptides.Type: GrantFiled: April 8, 2005Date of Patent: June 23, 2009Assignee: Zealand Pharma A/SInventors: Bjarne Due Larsen, Jørgen Søberg Petersen, Daniel R. Kapusta, Kenneth W. Harlow